Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001104659-26-015415·CASI Pharmaceuticals, Inc.
Schedule 13G ownership disclosure
CASI PHARMACEUTICALS INC
Ordinary Shares, par value $0.0001 · CUSIP: G1933S101
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Foresite Capital Fund VI LP
Shares: 0.00 · Class: 0%
- Foresite Capital Management VI LLC
Shares: 0.00 · Class: 0%
- James Tananbaum
Shares: 0.00 · Class: 0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-26-015415
- Form type
- SCHEDULE 13G/A
- Filer
- CASI Pharmaceuticals, Inc.
- CIK
- CIK 1962738
- Filed
- Feb 13, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership